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AAV adeno-associated virus
Ad adenovirus
Ang angiopoietin
BEC blood vascular endothelial cell
CAR coxsackie/adenovirus receptor
CFTR cystic fibrosis transmembrane regulator
E embyonic day
EC endothelial cell
ECM extracellular matrix
Flk-1 fetal liver kinase 1 (mouse VEGFR-1)
Flt-1 fms-like tyrosine kinase-1 (VEGFR-2)
Flt-4 fms-like tyrosine kinase-4
FOXC2 forkhead box C2
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HIF-1       hypoxia-inducible factor 1
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KDR kinase insert domain containing receptor (human VEGFR-2)
LEC lymphatic endothelial cell
LYVE-1 lymphatic vessel endothelial hyaluronan receptor-1
mRNA        messenger ribonucleid acid
NRP             neuropilin
PDGF          platelet-derived growth factor
PDGFR        platelet-derived growth factor receptor
PECAM-1  platelet endothelial cell adhesion molecule-1
PlGF            placenta growth factor
Prox-1           prospero-related homeobox protein-1
SLC              secondary lymphoid organ chemokine
Tek               tunica interna endothelial cell kinase (Tie-2)
Tie                tyrosine kinase with Ig and EGF homology domains (Tie-1)
TK                tyrosine kinase
VEGF           vascular endothelial growth factor
VEGFR        vascular endothelial growth factor receptor
VPF              vascular permeability factor (VEGF)
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7ABSTRACT
The lymphatic vasculature is essential for the maintenance of normal fluid balance and for
the immune response, but it is also involved in a variety of diseases. Hypoplasia or
dysfuction of the lymphatic vessels can lead to lymphedema, whereas hyperplasia or
abnormal growth of these vessels are associated with lymphangiomas and
lymphangiosarcomas. Lymphatic vessels are also involved in lymph node and systemic
metastasis of cancer cells. Recent novel findings on the molecular mechanisms involved in
lymphatic vessel development and regulation allow the modulation of the lymphangiogenic
process and specific targeting of the lymphatic endothelium. So far, two peptide growth
factors have been found which are capable of inducing the growth of new lymphatic vessels
in vivo in a process called lymphangiogenesis. These growth factors, VEGF-C and VEGF-D
belong to the  VEGF family of growth factors which also includes VEGF, placenta growth
factor (PlGF) and VEGF-B. VEGF-C and VEGF-D are ligands for the endothelial cell
specific tyrosine kinase receptors VEGFR-2 and VEGFR-3. In adult human as well as in
mouse tissues VEGFR-3 is expressed predominantly in lymphatic endothelial cells which
line the inner surface of lymphatic vessels. While VEGFR-2 is thought to be the main
mediator of angiogenesis, VEGFR-3 signaling is crucial for the development and
maintenance of the lymphatic vessels. Heterozygous inactivation of the VEGFR-3 tyrosine
kinase leads to primary lymphedema due to defective lymphatic drainage in the limbs.
In order to develop targeted therapy approaches for diseases involving the lymphatic
vasculature  it is important to understand the basic biology of the growth factors modulating
lymphatic vessels. The present study was undertaken to characterize the expression patterns
of VEGF-C and VEGF-D and their receptor VEGFR-3 in human tissues and to further study
their in vivo effects on blood and lymphatic vessel growth. VEGFR-3 was confirmed to be
specific for the lymphatic endothelium in most tissues, but its expression was also detected in
certain fenestrated and discontinuous blood vessel endothelia. In experimental animal models
VEGF-C induced lymphatic vessel growth, i.e. was lymphangiogenic, but high levels of
VEGF-C also resulted in blood vessel leakiness and growth. The VEGFR-3-specific mutant
form of VEGF-C called VEGF-C156S lacked these side effects but was sufficient for
therapeutic lymphangiogenesis in a mouse model of lymphedema. The results show that
VEGF-C156S is a specific lymphatic endothelial growth factor in the skin and an attractive
molecule for pro-lymphangiogenic therapy.
8REVIEW OF THE LITERATURE
The formation of blood and lymphatic vessel networks during embryonic
development
Vasculogenesis and angiogenesis
All proliferating or developing tissues and tumors, are dependent on oxygen and nutrients
supplied by the vascular system. During embryogenesis, the development of the vascular
system occurs via two processes, vasculogenesis and angiogenesis (Figure 1). Vasculogenesis
involves the de novo differentiation of endothelial cells (ECs) from mesoderm-derived
precursor cells, called hemangioblasts (Risau and Flamme, 1995). The EC precursors
(angioblasts) and the hematopoietic cell precursors are thought to be derived from common
precursor cells. According to this theory, the hemangioblasts aggregate to form primary blood
islands in which the cells in the interior differentiate into hematopoietic stem cells whereas the
cells in the periphery differentiate into angioblasts. The angioblasts then cluster and
reorganize to form capillary-like tubes. Circulating endothelial progenitor cells (EPCs) have
been isolated in peripheral blood of adult tissue, and some data suggests that these cells can
participate in postnatal formation of new blood vessels (postnatal vasculogenesis/
angiogenesis) (Asahara et al., 1997; Shi et al., 1998; Springer et al., 1998).
Once the primary vascular plexus is formed, new capillaries form by sprouting or by splitting
(intussusception) from pre-existing vessels in the process called angiogenesis (Figure
1)(Risau, 1997). The newly formed vasculature is further remodeled into a more mature tree-
like hierarchy of vessels containing vessels of different sizes. Excess branches are pruned,
some vessels regress and others fuse to form larger ones. In the primary capillary plexus the
ECs start to differentiate into arterial or venous type (Yancopoulos et al., 1998). ECs become
surrounded by pericytes and smooth muscle cells and formation of the extracellular matrix
(ECM) and particularly the basal lamina gives support to the vessels. In pathological
angiogenesis maturation and stabilization of the vessels occur improperly and the vessels
remain immature (Hashizume, 2000; Shunichi, 2002). Tumor blood vessels are leaky and as
unstable vessels they are dependent on continuous growth factor stimulation for survival.
Endothelial cell differentiation
In adults the blood vessel network consists of a very heterogeneous group of ECs. ECs
function in a variety of physiological situations, and therefore the capillary endothelium of
each individual normal tissue is highly specialized (Cotran, 1999; Ruoslahti and Rajotte, 2000).
Tumor vasculature has also been shown to express its own specific markers (Ruoslahti and
Rajotte, 2000). Tissue-specific vascular markers provide new opportunities for the targeting of
therapeutic compounds, such as genes and drugs, to the endothelial cells thus avoiding
unwanted systemic toxicity.
9Figure 1 Schematic illustration of vasculogenic and angiogenic processes in developing embryos. In
vasculogenesis, mesodermal cells first differentiate into hemangioblasts, whereafter endoderm-
mesoderm interactions are required for further blood island differentiation (Risau and Flamme, 1995).
After the primary capillary plexus has been formed, new vessels are generated via angiogenesis (Risau,
1997). During sprouting angiogenesis, ECs degrade the underlying basement membrane, migrate,
proliferate and reassemble into tubes. In non-sprouting angiogenesis, new vessels are formed by
intussusceptive growth or the existing vessels increase in size through intercalated growth. The formed
vasculature is remodelled into a more mature tree-like hierarchy containing vessels of different sizes
when excess branches are pruned, some vessels regress and others fuse to form larger vessels. The
vessels further differentiate by recruitment of pericytes and smooth muscle cells. Formation of the extra
cellular matrix and particularly the basal lamina gives support to the vessels. Arterio-venous
differentiation is regulated by Ephrin, Notch and Neuropilin family members (Adams, 1999; Wang,
1998; Lawson, 2001; Herzog, 2001). Some growth factors or their receptors mediating blood vessel
growth and maturation are indicated on the right.
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Blood vessels are divided into arteries, arterioles, capillaries, venules and veins depending on
their size, function and morphology. Capillaries are the smallest vessels and they are
responsible for nutrient and oxygen diffusion to the tissues. The degree of permeability of
capillaries depends on the nature of the intercellular junctions adjoining the cells, and also on
the transendothelial transport properties and morphology of the ECs (Dejana, 1995). In general,
the endothelia of capillaries in adult tissues can be subdivided into three groups: continuous,
fenestrated and discontinuous or sinusoidal capillary endothelia (Figure 2). Typical organs
that contain continuous capillary endothelia are skeletal muscle, skin and the central nervous
system. The exchange of molecules is strictly controlled in these tissues and in the central
nervous system the permeability of blood vessels is further restricted by a special blood brain
barrier.
Fenestrated capillaries are characterized by the presence of fenestrations, special channels
across the endothelial cells, 80-100 nm in diameter. These channels appear to be closed by a
thin diaphragm. Fenestrated capillaries also have pinocytotic vesicles. One theory suggests
that fenestrations are formed when a pinocytotic vesicle spans a narrow cytoplasmic layer
and opens, simultaneously, on both surfaces (Ross, 1995). In the gastrointestinal tract and in
the gallbladder the capillaries are thicker and have few fenestrations when absorption is not
occuring. However, during the absorption of nutrients and production of bile in the
gallbladder, the numbers of both pinocytotic vesicles and fenestrae increases rapidly (Ross,
1995). Fenestrated capillary endothelia can also be found in other sites where there is a
special need for regulation of blood vessel permeability and molecule transport across the EC
wall, including the endocrine glands and nasal respiratory mucosa. Special discontiuous, or
sinusoidal, capillary endothelia can be found in the liver, spleen and bone marrow. Basal
lamina and occasional pericytes are present in continuous and fenestrated capillary endothelia
but in sinusoidal capillaries these structures can be totally absent and unusually wide gaps
can be found between ECs.
Lymphangiogenesis
In humans, the first lymph sacs have been found in 6 to 7 week old embryos (van der Putte,
1975). This is nearly 1 month after the development of the first blood vessels. There are two
theories about the origin of the lymphatic vessels. A century ago Sabin proposed that the
primitive lymph sacs originate by EC budding from the pre-existing embryonic veins (Figure
3) (Sabin, 1902). The peripheral lymphatic system would then spread from these primary
lymphatic sacs by sprouting. Later during the development most of the lymph sacs
differentiate to form primary lymph nodes and the blood is removed from the lymphatic
network to the veins as they become functional (Clark, 1912). An alternative model suggests
that the initial lymph sacs arise in the mesenchyme from precursor cells, independent of
veins, and that the connection to the venous system is formed later in development
(Huntington and McClure, 1908). Recently two lymphatic specific markers, VEGFR-3 and
Prox1, have been show to be expressed in the endothelium lining the budding lymphatic sacs
in mouse embryos, supporting Sabin’s theory of lymphatic development (Dumont, 1998;
Kaipainen, 1995; Wigle and Oliver, 1999). However, in a quail-chick chimera model mesodermal
lymphangioblasts, lymphatic precursor cells, were shown to participate in the development of
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the lymphatic system, supporting the theory that the peripheral lymphatic vessels develop by
multiple mechanisms (Schneider, 1999; Wilting, 1999; Wilting, 2000). Whether
lymphangioblasts can participate in lymphangiogenesis in adult mammals is still to be
determined.
Figure 2. Schematic illustration of capillary endothelia types of blood and lymphatic vessels. In the
upper lane light grey/yellow marks pericytes and dark grey/red marks blood vessel ECs. In the
continuous and fenestrated capillaries the basal lamina is continuous, whereas in the sinusoidal
capillaries the basal lamina is discontinuous. Lymphatic capillaries are irregular and thin-walled and
contain anchoring filaments that attach them to the ECM.
Characteristics of lymphatic vessels
Lymphatic vessels differ from blood vessels in several ways. Lymphatic capillaries are
essentially thin-walled and blind-ended endothelial tubes that, unlike typical blood
capillaries, lack pericytes and continous basal lamina and contain large interendothelial pores
(Figure 2) (Barsky, 1983; Casley-Smith, 1980; Ezaki, 1990; Oh, 1997). Lymphatic capillaries also
contain anchoring filaments that connect the vessels to the ECM (Casley-Smith, 1980). These
filaments are thought to maintain the patency of the vessels during increased tissue pressure
and inflammation.  Due to their greater permeability, lymphatic capillaries are more effective
than blood capillaries in removing protein-rich fluid from intercellular spaces. In the small
intestine, lymphatic vessels serve as conveyers of large proteins and lipids that can not get
across the fenestrae of the absorptive capillaries (Ross, 1995). Large collecting lymphatic
12
Figure 3. Scheme illustrating the formation of lymphatic vessels. A widely accepted theory suggests
that during the embryonic period lymphatic vessels are generated from the veins. A subpopulation of
the ECs in the embryonic veins differentiate to lymphatic ECs (lymphatic commitment) and lymphatic
sacs are formed by sprouting or budding from the veins in a process that is called
“lymphvasculogenesis”. Lymphatic vessels sprout, expand, remodel and establish a blind-ended vessel
system that is connected to the venous system. In addition, lymphatic precursor cells may differentiate
to lymphatic ECs and form new vessels. Transcription factor Prox1 and tyrosine kinase receptor
VEGFR-3 are thought to participate in lymphatic differentiation and growth as discussed in later
chapters. Angiopoietins may play role in the remodelling of the primary lymphatic vessel network.
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vessels contain connective tissue and bundles of smooth muscle in their wall as well as
valves, which prevent the backflow of lymph (Ross, 1995). Unlike in the blood vessel system
there is no central pump in the lymphatic vessel network in mammals. Lymph is driven in the
tissues by the compression of the primary lymphatic vessels by adjacent skeletal muscles.
Contractility of the collecting lymphatic vessel wall also contributes to lymphatic vessel
function (Berens von Rautenfield, 1993; Wilting, 1999). When the lymph vessel becomes
streched with fluid the wall of the vessels automatically contracts. Valves in the lymphatic
vessels further aid the unidirectional flow in the vessel network. Some tissues, such as brain,
retina, bone marrow and cartilage totally lack the lymphatic vessels.
Lymphoid organs such as lymph nodes, tonsils, Peyer’s patches, spleen and thymus, are part
of the lymphatic system. Besides fluid transport, the lymphatic system has an important role
in immunological responses. As the lymph circulates in the lymphatic vessels, it passes
through lymph nodes, where it is exposed to cells of the immune system. In the lymph nodes
foreign substances (antigens) are concentrated by the dendritic cells and presented to
lymphocytes. This leads to a cascade of steps that results in immune responses. Lymphocytes
circulate between the lymphatic and blood vasculature. Lymphocytes that enter lymphatic
vessels in peripheral tissues, enter the lymph nodes via the afferent lymphatic vessels.
Lymphocytes may also enter the lymph node through the wall of special postcapillary
venules that are called the high-endothelial venules (HEV). Lymphocytes are then
recirculated to the blood circulation along with lymph via the efferent lymphatic vessels and
the thoracic duct. Lymphocyte passage across the endothelium is guided by several adhesion
molecules, including the integrins, selectins and their ligands (Butcher, 1999; Kunkel, 2002;
Rosen, 1999; Tedder , 1995). The trafficking of the antigen presenting cells, the dendritic cells
and Langerhans cells, from the peripheral tissues to the lymphatic vessels is also regulated by
different cell adhesion molecules and chemokine signalling  cascades. For example, the
activated dendritic cells upregulate the cytokine receptor CCR7 in order to become sensitive
to secondary lymphoid tissue chemokine (SLC) that is constitutively produced by the
lymphatic endothelial cells in the skin (Cyster, 1999; Gunn, 1998). Interestingly, it has recently
been shown that certain human breast cancer cell lines also express the CCR7 receptor
(Muller, 2001). In an experimental animal model expression of CCR7 enhanced lymphatic
metastasis of the melanoma cells 10-fold as compared to control tumor cells, neutralizing
anti-SLC were capable of blocking this effect (Viley, 2001). Tumor cells may therefore use
the same trafficking pathways as the lymphocytes and antigen presenting cells in order to
gain access to the lymphatic vessels.
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Molecular regulation of the blood and lymphatic vessel growth
Both angiogenesis and lymphangiogenesis are tightly regulated by intercellular signalling
mechanisms, growth factors and cytokines. The angiogenic switch, in tumors for instance, is
thought to be caused by a shift in the net balance of positively acting angiogenic mediators
and negatively acting angiogenesis inhibitors. The mechanisms underlying this shift of
balance are incompletely understood, but several factors including oncogenes, tumor
suppressor genes and hypoxia are known to contribute to the regulation of this balance by
causing up- or down-regulation of endogenous angiogenesis inhibitors and pro-angiogenic
growth factors (Hanahan, 1996; Kerbel, 1998). Regulation of the lymphangiogenesis is however
much less well understood.
VEGF and its receptors
VEGF, or VEGF-A, is a major regulator of vasculogenesis and angiogenesis, but it is also
required for generation of blood cells and for homing of leukocytes to sites of inflammation
(Ferrara, 1999b; Yancopoulos, 2000). VEGF has been shown to play a role in pathological
angiogenesis in many diseases, including tumors, psoriasis, rheumatoid arthritis and several
intraocular syndromes (Ferrara, 1999a, Folkman, 1995). VEGF inhibitors are currently being
tested in numerous clinical trials  (Ferrara and Alitalo, 1999). On the other hand VEGF gene
transfer has been used in proangiogenic therapy trials in ischemic diseases (Blau and Banfi,
2001; Isner, 2002; Ylä-Herttuala, 2001).
VEGF is a highly specific mitogen for vascular ECs (Conn, 1990; Connolly, 1989; Ferrara and
Davis-Smyth, 1997; Ferrara and Henzel, 1989; Gospodarowicz, 1989; Keck , 1989; Leung, 1989;
Plouet, 1989). Inactivation of only a single VEGF allele in mice resulted in embryonic lethalty
due to defective angiogenesis (Carmeliet, 1996; Ferrara, 1996). There is also strong evidence
that VEGF is a survival factor for ECs, both in vitro and in vivo (Alon, 1995; Benjamin and
Keshet, 1997; Gerber, 1998; Yuan, 1996). It has been proposed that pericyte coverage of newly
formed vessels is the critical event that determines when ECs no longer require VEGF for
survival in vivo (Benjamin, 1998).
VEGF is also known as vascular permeability factor, as it is a potent inducer of the vascular
leak (Bruce, 1987; Dvorak, 1995; Senger, 1983). It has been shown to induce fenestrations in
adrenal cortex capillary ECs in culture (Esser, 1998; Roberts and Palade, 1995). Furthermore,
inhibition of VEGF activity by specific monoclonal antibodies reduces vascular permeability
(Dvorak, 1995; Mesiano, 1998).
VEGF is expressed as several isoforms of different amino acid chain lengths (VEGF121,
VEGF145, VEGF165, VEGF183, VEGF189, VEGF206) that differ in their ability to bind heparin
and neuropilin–1 (NRP-1) (Houck, 1991; Jingjing, 1999; Poltorak, 1997; Soker, 1998; Tischer,
1991). VEGF121, that fails to bind to NRP-1 and heparin, is a freely diffusible protein (Houck,
1992; Soker, 1998). Due to heparin binding, a significant fraction of secreted VEGF165 remains
bound to the extracellular matrix (Houck, 1992). The VEGF isoforms VEGF189 and VEGF206
bind heparin with the highest affinity and are almost completely sequestered in the ECM
(Park, 1993). Results from several in vivo models have suggested that VEGF165 is the most
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efficient VEGF isoform for inducing angiogenesis (Grunstein, 2000; Stalmans, 2002). The fact
that VEGF165 is present in  ECM and as a diffusing molecule may facilite the formation of the
concentration gradient of the ligand that is required for EC migration. In addition, binding to
the NRP-1 receptor may also explain why VEGF165 is a more efficient EC mitogen than
VEGF121.
VEGF receptors
VEGF binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR) receptors in the ECs with high
affinity (Figure 4) (De Vries, 1992; Millauer, 1993; Quinn , 1993; Terman, 1992). Both VEGFR-1
and -2 have seven immunoglobulin (Ig) –homology domains in the extracellular domain, a
single transmembrane region and a tyrosine kinase (TK) domain, which is interrupted by a
kinase-insert domain (Matthews, 1991; Shibuya, 1990; Terman, 1991). Embryos lacking VEGFR-
2 fail to develop blood islands,  embryonic vasculature and mature hematopoietic cells
(Shalaby, 1997; Shalaby, 1995). VEGF mutants and viral VEGF-E that bind selectively to
VEGFR-2 are able to induce mitogenesis, chemotaxis and increased vessel permeability in
vivo (Keyt, 1996; Meyer, 1999; Wise, 1999; Gille, 2001). In vitro VEGFR-2 undergoes strong
tyrosine phosphorylation after VEGF stimulation, whereas VEGFR-1 phosphorylation is very
weak (Waltenberger, 1994; Seetharam., 1995). In VEGFR-1 deficient mice there is excess of ECs
that fail to assemble into tubes to form a functional vessel network whereas mice expressing
VEGFR-1 lacking the tyrosine kinase domain show no vascular phenotype (Fong,, 1995;
Hiratsuka, 1998; Fong, 1999). These studies suggest that during the development VEGFR-1
may be non-signalling and function as a regulator of the bioavailability of VEGF. VEGFR-2
has been considered to be the key signalling receptor for VEGF in the ECs, but recent results
have suggested that VEGFR-1 mediated signalling may play an important role in
pathological angiogenesis and inflammation (Carmeliet, 2001).
In addition to ECs, VEGFR-1 is expressed in monocytes, macrophages, pericytes, placental
trophoblasts, renal mesangial cells and in some bone marrow derived hematopoietic stem
cells whereas VEGFR-2 can be found in megakaryocytes, platelets, retinal progenitor cells,
some hematopoietic stem cells and in circulating endothelial precursor cells (Barleon, 1994;
Charnock-Jones, 1994; Sundberg,, 2001a; Clauss, 1990; Katoh, 1995; Ziegler, 1999; Ziegler, 1993;
Hattori, 2002). VEGFR-1 signalling  induces monocyte migration and recent data suggest that
VEGFR-1 signalling also promotes the survival and recruitment of bone marrow derived
stem cells (Clauss, 1996; Gerber, 2002; Hattori, 2002; Luttun, 2002).
Neuropilins (NRP-1 and -2) are receptors for the collapsin/semaphorin family which regulate
neuronal cell guidance (Fujisawa, 1997; Fujisawa, 1998).  In past years NRPs have been shown
to be expressed in certain blood and lymphatic vessel ECs and they bind to VEGF in an
isoform specific manner (Soker, 1996; Soker, 1998; , Karkkainen, 2001; Gluzman-Poltorak, 2000).
In the ECs NRPs seem to function as accessory receptors that enhance or regulate the
signalling of VEGFs
 
via VEGF receptors by forming receptor complexes  (Soker, 1998;
Yamada, 2001; Gluzman-Poltorak, 2001). Mice lacking NRP-1 exhibit deficiences in the
development of the cardiovascular system suggesting that NRP-1 is required for VEGF
induced vasculogenesis and angiogenesis (Kawasaki, 1999; Yamada, 2001). NRP-2 acts as a
receptor for splice isoforms VEGF145 and VEGF165 (Gluzman-Poltorak, 2000) NRP-2 is
expressed by human ECs but mice lacking NRP-2 do not have cardiovascular malformations
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(Chen, 2000; Giger, 2000; Gluzman-Poltorak, 2000).
Regulation of the VEGF expression
Expression of VEGF is upregulated by hypoxia and VEGF mRNA is often upregulated near
areas of tumor necrosis (Plate, 1992; Shweiki, 1992). In hypoxic tissues the hypoxia inducible
factor-1 (HIF-1) transcription factor has a central role in inducing the transcription of genes
that are involved in glycolysis and angiogenesis, including VEGF (Gleadle, 1998). VEGF
expression is also stimulated by oncogenes, for example by members of the Ras and erbB
families (Okada, 1998; Viloria-Petit, 1997), whereas certain tumor suppressor genes, including
the LKB1 and the von Hippel-Lindau (vHL) tumor suppressor gene products, appear to limit
the production of VEGF (Gnarra., 1996; Maxwell, 1999; Siemeister, 1996; Ylikorkala, 2001).
VEGF expression has also been shown to be regulated by estradiol in human breast cancer
cells and a functional estrogen response element was identified in the regulatory region of the
VEGF gene (Hyder, 2000).
VEGF-B and PlGF
VEGF-B has two splice isoforms, VEGF-B167 and VEGF186, that are differentially expressed
with a predominant expression of VEGF-B167 (Li, 2001; Olofsson, 1996). VEGF-B is a ligand
for VEGFR-1 and its isoforms differ in their binding to heparin and to NRP-1 (Olofsson, 1998;
Mäkinen, 1999). Expression of VEGF-B is not upregulated by several studied growth factors,
hypoxia or oncogenes (Enholm, 1997). In adult tissues, VEGF-B expression is abundant in the
heart and skeletal muscle (Olofsson, 1996). VEGF-B deficient mice are otherwise healthy and
fertile, but they display atrial conduction defects or reduced heart size (Aase, 2001; Bellomo,
2000). In addition, VEGF-B knock out mice show impaired recovery and vascular function
after experimentally induced myocardial ischemia (Bellomo, 2000).
PlGF is another member of the VEGF family of growth factors that binds specifically to
VEGFR-1 (Maglione, 1991; Park, 1994). PlGF was originally discovered in the human placenta
and it has two isoforms, PlGF-1 and -2  (Cao, 1997; Maglione, 1991; Maglione, 1993; Migdal,
1998). PlGF-2 is able to bind to NRP-1 and heparin. Both VEGF-B and PlGF form
heterodimers with VEGF, and VEGF/PlGF heterodimers have been shown to bind to the
VEGFR-2 receptor (Olofsson, 1996b; Cao, 1996; DiSalvo, 1995). In culture PlGF homodimers
are chemotactic for monocytes and ECs (Clauss, 1996), but PlGF alone is not capable of
inducing EC proliferation or vascular permeability (Park, 1994). Interestingly, high
concentrations of PlGF that saturate the VEGFR-1 sites for binding, have been shown to
potentiate the activity of VEGF both in vivo and in vitro, suggesting that VEGFR-1 may act
as a decoy receptor for VEGF in the ECs (Park, 1994). PlGF deficient mice or even double
knockout mice lacking both PlGF and VEGF-B do not have an obvious phenotype (Carmeliet,
2001). However, loss of PlGF impairs angiogenesis, plasma extravasation and collateral
growth during ischemia, inflammation, wound healing and cancer (Carmeliet, 2001).
Transplantation of wild type bone marrow rescued the impaired angiogenesis and collateral
growth in PlGF deficient mice, indicating that PlGF might contribute to blood vessel growth
by mobilizing the bone-marrow derived EC precursor cells (Carmeliet, 2001). Recent reports
also show that VEGFR-1 is expressed in some bone marrow derived hematopoietic stem cells
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and that PlGF promotes and anti-VEGFR-1 antibody inhibits the recruitment of the myeloid
stem cells from the bone marrow (Hattori, 2002; Luttun, 2002). VEGFR-1 is also expressed in
monocyte/macrophages and in pericytes (Sundberg, 2001a; Clauss, 1990). Recent reports
suggest that PlGF and possibly also VEGF-B play role in pathological angiogenesis by
increasing the recruitment of bone marrow derived myeloid and ECs precursor cells,
inflammatory cells and pericytes and by enhancing the effects of VEGF (Carmeliet, 2001;
Luttun, 2002; Hattori, 2002).
Figure 4. Receptor binding specificity of VEGF family members. VEGFR-2 is the main receptor for
VEGF in the ECs. VEGFR-1 signalling mediates monocyte migration and according to recent data,
recruitment of VEGFR-1+ stem cells from the bone marrow. Role of VEGFR-1 signalling in the ECs is
poorly defined. VEGFR-3 signalling regulates lymphatic vessel growth. Neuropilins (NRPs) function as
isoform specific accessory receptors for some VEGF family members.
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VEGF-C, VEGF–D and their receptors
VEGF-C and VEGF-D were the first characterized growth factors capable of inducing
growth of new lymphatic vessels in vivo (Achen, 1998; Joukov, 1996; Jeltsch, 1997; Oh, 1997).
VEGF-C and VEGF-D activate the endothelial cell -specific tyrosine kinase receptors
VEGFR-2 and VEGFR-3 (Achen, 1998; Joukov, 1996). VEGF-C is mitogenic for lymphatic
ECs and induces a selective lymphangiogenic response in differentiated avian chorioallantoic
membrane (Oh, 1997). Accordingly, overexpression of VEGF-C or VEGF-D in transgenic
mice induces development of a hyperplastic lymphatic vessel network (Jeltsch, 1997; Veikkola,
2001). Recent data also suggest that a VEGFR-3 specific mutant of VEGF-C (VEGF-C156S)
is lymphangiogenic when overexpressed in the skin of transgenic mice (Joukov, 1998;
Veikkola., 2001). Conversely, inhibition of lymphatic growth was obtained when VEGF-
C/VEGF-D binding to their receptors was blocked by a soluble form of the extracellular
domain of VEGFR-3 in a similar transgenic mouse model  (Mäkinen, 2001a).
Figure 5. Proteolytic processing of VEGF-C (and VEGF-D).. The growth factors are synthesized as
prepropolypeptides containing signal sequence, N- and C- terminal propeptides and the VEGF-
homology domain (VHD). Proteolytic processing increases the binding affinity to VEGFR-3 and only
the fully processed 21kDa form of VEGF-C is able to bind to VEGFR-2. The numbers indicate the
approximate molecular masses (kDa) of the corresponding polypeptides under reducing conditions.
Modified from Joukov, 1997
Proteolytic cleavage, by as yet uncharacterized proteases, is an important regulator of
receptor binding and thus, the biological activity of VEGF-C and VEGF-D (Figure 5)
(Joukov, 1997; Stacker, 1999). Partially processed forms of VEGF-C and VEGF-D are able to
bind and to activate VEGFR-3, while the fully processed short forms are also potent
stimulators of VEGFR-2. Presumably, via VEGFR-2 VEGF-C can induce capillary EC
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migration and proliferation in culture (Joukov, 1996; Joukov, 1997) and stimulate angiogenesis
in the cornea and ischemic muscle (Cao, 1998; Witzenbichler, 1998). The proinflammatory
cytokines IL-1ß and TNF-α upregulate VEGF-C mRNA, whereas both dexamethasone and
an IL-1 receptor antagonist inhibited this effect (Ristimaki, 1998). The short form of VEGF-C
has been shown to increase blood vessel permeability in vivo as a recombinant protein
(Joukov, 1998). However, very little is known about the proteolytic processing of VEGF-C/D
in different tissues.
The VEGFR-3 tyrosine kinase receptor is expressed predominantly in the ECs lining the
inner surface of lymphatic vessels in adult murine tissues (Aprelikova, 1992; Galland, 1993;
Pajusola, 1992; Kaipainen, 1995). During embryogenesis, VEGFR-3 is first expressed in blood
vascular ECs (Kaipainen, 1995). Accordingly, mice deficient in the VEGFR-3 gene show
abnormal remodelling of the primary vascular plexus and die at E9.5 (Dumont, 1998).
However, during further development VEGFR-3 is abundant in the lymphatic endothelium
and downregulated elsewhere. The lymphangiogenic effect of VEGF-C/VEGF-D is thought
to be mediated via VEGFR-3 (Veikkola, 2001). Interestingly, NRP-2, a receptor for various
VEGFs on venous endothelia and semaphorins on neural cells, may act as a co-receptor for
VEGF-C in some lymphatic vessels (Herzog,, 2001; Karkkainen, 2001).
Angiopoietins and their Tie-receptors
In addition to VEGFs, angiopoietins have also been shown to play a role in the formation of
the vascular system. To date there are four known angiopoietins, which all bind to the Tie-2
receptor, mediating vessel stabilization signals, whereas the Tie-1 receptor has no known
ligand (Davis, 1997; Kim, 1999; Maisonpierre, 1997; Valenzuela, 1999). The phenotypes of Tie-2
and Ang1 deficient mice suggest a role for this ligand-receptor system in maintaining the
communication between ECs and the surrounding mesenchyme, in order to establish stable
cellular and biochemical interactions between ECs and pericytes/smooth muscle cells
(Dumont, 1994; Puri, 1995; Suri, 1996). An activating mutation of Tie-2 was shown to cause
hereditary venous malformations characterized by dilatation of blood vessels and deficient
smooth muscle coverage of vessels (Vikkula, 1996). On the other hand, overexpression of
Ang1 in the skin of transgenic mice demonstrated that Ang1 can induce a hypervascular
phenotype with increase in the size but not number of vessels (Thurston, 1999). Ang1 reduces
vascular leakage even in the presence of excess VEGF (Thurston, 1999). Adenovirally mediated
Ang1 administration also protected adult vasculature against plasma leakage, but it essentially
lacked the effects on blood vessel morphology seen in the trangenic model (Thurston, 2000).
The expression of Ang2, an antagonist of the Tie-2 receptor, has been detected at sites of
active angiogenesis, including tumors (Holash, 1999; Maisonpierre, 1997). Ang2 is thought to
play a role in destabilizing quiescent adult vessels, and thus to be involved in the initiation of
vascular remodelling. The study of the Ang-2 null mouse has revealed that the angiopoietins
are also likely to play roles in the lymphatic development (Gale, 2002). Mice lacking Ang-2
have lymphatic defects, but the expression of Ang-1 in the Ang-2 locus is sufficient to rescue
the lymphatic phenotype, suggesting that both Ang1 and Ang2 may play role in
lymphangiogenesis as agonists.
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Ephrins
Recently, Eph receptor tyrosine kinases and their cell-surface-bound ephrin ligands were
found to have a role in defining boundaries between arterial and venous vascular domains
(Adams, 1999; Holder, 1999; Wang, 1998). In addition to vascular development, members of this
growth factor family also participate in the regulation of  axon guidance and bundling in the
developing brain, control of cell migration and adhesion, and in the tissue patterning of the
embryo (Wilkinson, 2001). A characteristic feature of the Eph/ephrin family is that membrane
bound tyrosine kinase receptors bind to their multimeric,  membrane bound ligands, which
results in bidirectional signalling between the interacting cells (Schmucker and Zipursky, 2001).
Ligands of the Ephrin B family were also found to induce capillary sprouting in vitro (Adams,
1999). Interestingly, the phenotypes of the mice lacking ephrin-B2 or EprinB4 resembles the
phenotype of the mice lacking either Ang1 or Tie-2 (Adams, 1999; Gerety, 1999; Wang, 1998).
Deficient signalling of both cascades leads to aberrant vessel remodelling and sprouting and
to abnormal heart trabeculation, suggesting that the Ang1/Tie2 and ephrin-B2/EphB4
signalling cascades may interact.
During development NRP-1 expression is restricted to the arteries whereas NRP-2 is
expressed in veins, suggesting that neuropilins may also play role in arterio-venous
differentiation (Herzog, 2001). In addition, signalling via  Notch induces expression of arterial
genes and suppresses venous specific genes (Lawson, 2001)
Lymphatic vessel markers
The first imaging techniques of the lymphatic vessels involved injection of dyes that are
specifically taken up by the lymphatic vessels. Dyes, such as Patent Blue and fluorescent
conjugates of high molecular weight material, including FITC-dextran, are still used both in
patient and animal work. Until recently, immunohistochemical identification of the lymphatic
vessels has been somewhat complicated. The small lymphatic vessels lack a continuous basal
lamina and based on this finding lymphatic capillaries have been identified by using
antibodies that stain basement membranes, including antibodies against type IV collagen or
laminin (Barsky, 1983). The lymphatic endothelium also contains a specific types of EC
adhering junction. One component in these junctions is desmoplakin, a feature that can be
used to identify lymphatic vessels (Schmelz and Franke, 1993). Furthermore, 5’nucleotidase
activity of the lymphatic endothelium has been used in several histochemical studies (Kato,
1990; Shimoda, 2001). In frozen sections of human tissues, double staining for blood vessel
specific marker PAL-E and some panendothelial cell marker can also be used to define the
lymphatics (Schlingemann, 1985).
VEGFR-3 was the first lymphatic endothelial cell (LEC) marker found, but more recently
other LEC markers have also been characterized (Table 1). The transcription factor Prox1
has been shown to be required for the programming of LEC differentiation during
embryogenesis (Wigle, 2002; Wigle and Oliver, 1999). Prox1 is expressed in a subpopulation of
the ECs that are budding and sprouting from the embryonic veins to give rise to lymphatic
sacs, Prox1 deficient mice are devoid of lymphatic vasculature (Wigle, 2002; Wigle and Oliver,
1999). Prox1 is expressed in a variety of different cell types but among endothelial cells its
expression is restricted to the lymphatic endothelium (Wigle and Oliver, 1999).
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The lymphatic endothelial hyaluronan receptor (LYVE-1) is a CD44 homologue that was
identified as a cell surface protein specific for LECs and activated tissue macrophages
(Banerji, 1999; Jackson, 2001).  However, LYVE-1 is also expressed by  sinusoidal ECs in the
liver and spleen and some blood capillary ECs in the lung (Carreira, 2001; T. Partanen, D.
Jackson personal communication). LYVE-1 binds hyaluronan (HA), an abundant tissue
glycosaminoglycan, that plays a role in the maintenance of tissue integrity and in cell
migration (Jackson, 2001). In the lymphatic vessels, LYVE-1 seems to play a role in
transporting HA across the lymphatic vessel wall (Jackson, 2001). Further studies should
reveal whether LYVE-1-HA interactions are involved in leukocyte migration and tumor
metastasis.
Another recently described novel marker for the lymphatic endothelium is podoplanin
(Breiteneder-Geleff, 1999). In addition to the lymphatic endothelium, this surface glycoprotein
is expressed in several other cell types including kidney podocytes, osteoblastic cells and
lung alveolar cells (Wetterwald, 1996). The function of podoplanin in the lymphatic
endothelium is not known. Detailed comparison of the expression patterns of Prox1, VEGFR-
3, LYVE-1 and podoplanin in different endothelia and in the tumor vasculature requires
further study.
Table 1. Lymphatic vessel markers (Adapted from Jussila 2002)
Marker Protein class Biological effect
VEGFR-3 Receptor tyrosine kinase on ECs Lymphangiogenesis
Survival of LECs
LYVE-1 Receptor for extracellular matrix
glycosaminoglycan
Transport of hyaluronan from
tissues to lymph nodes(?)
 Podoplanin Integral membrane mucoprotein unknown
 Prox1 Homoebox transcription factor Involved in the budding and
sprouting of lymphatic vessels
during development
β-chemokine
receptor D6
Chemokine receptor in the afferent
lymphatics
Leukocyte recirculation
Macrophage
mannose receptor
Receptor in macrophages, lymphoid
organds, lymphatic endothelial cells,
perivascular microglia and glomerular
mesangial cells
Phagocytosis of microbes, viral
endocytosis
Desmoplakin Component of intercellular adherent
junctions
Cell-cell adhesion of LECs
Other markers of LECs include the macrophage mannose receptor (MR) and β-chemokine
receptor D6 (Irjala, 2001; Linehan, 1999; Nibbs, 2001). Besides being present in the lymphatic
endothelium the mannose receptor is also expressed in several non-endothelial cell types
22
(Linehan, 1999). In the lymphatic vessels the interaction between MR and L-selectin seems to
mediate lymphocyte binding (Irjala, 2001). The β-chemokine receptor D6 is expressed in a
subset of lymphatic vessels. In lymph nodes, D6 immunoreactivity is present on the afferent
lymphatic vessels suggesting that it may influence the chemokine-driven recirculation of
leukocytes through the lymphatic vessels (Nibbs, 2001).
In addition, there are also several other molecules which have been reported to be important
in lymphatic development, such as the transcription factor Net, integrin α9β1 and Ang-2
(Ayadi, 2001b; Huang, 2000; Gale, 2002). Recently, methods to isolate and culture LECs
separately from the blood vascular endothelial cells (BECs) have been published  (Kriehuber,
2001; Mäkinen, 2001b). Further studies of gene and protein expression patterns of these two
isolated cell populations should result in discovery of new lymphatic specific markers.
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Diseases associated with lymphatic vessel function
Impairment of lymphatic function is involved in various diseases, characterized by
inadequate transport of interstitial fluid, edema, impaired immunity and fibrosis (Rockson,
2001). On the other hand, abnormal proliferation of lymphatic endothelial cells takes place in
lymphangiomas, lymphangiosarcomas and possibly in Kaposi’s sarcoma (Witte, 1997).
Lymphatic vessels also serve as an important route for tumor metastasis. Very little was
known about the molecular mechanisms behind lymphatic diseases until very recently. The
first gene mutations causing human lymphedema have now been found and several mouse
models have facilitated the development of new therapeutic applications for lymphedema.
Animal tumor models have also been used to analyse mechanisms of tumor metastasis and to
test strategies for the inhibition of metastasis.
Lymphedema
Lymphatic vessels play a key role in the immune response to various antigens and in
maintaining fluid homeostasis in the body. Blockage of lymphatic drainage or an abnormal
development of the superficial lymphatic vessels leads to lymphedema, which is
characterized by a disfiguring and disabling swelling of the extremities (Witte, 1997).
Lymphedemas can etiologically be divided into two main categories. Primary lymphedemas
are rare developmental disorders whereas more common secondary lymphedema syndromes
are caused by infections, surgery or trauma. Secondary lymphedema can develop as the result
of inflammatory or neoplastic obstruction of the draining lymphatic vessels or for example
after breast cancer surgery. Approximately 35% of primary lymphedema patients have a
family history of the disease and it has been estimated that 1:6000 newborns develop primary
lymphedema, with a sex ratio one male to three females (Dale, 1985). Secondary lymphedema
is a relatively common disorder and it has been estimated that there are 3 to 5 million patients
with secondary lymphedema in the US. Lymphatic filariasis is the second leading cause of
permanent and long-term disability globally. Lymphatic filariasis is caused by a parasitic
infection of the lymphatic vessels and may lead to massive edema and deformation of the
limbs or genitals (Witte, 1997). According to the World Health Organization (WHO), over
120 million people suffer from filarial lymphedema worldwide. In all its forms, lymphedema
is a chronic disease in which persistent dysfunction of the lymphatic vessels gradually results
in dermal fibrosis, thickening of the skin and accumulation of adipose tissue.
Genetic alterations in lymphedema
The molecular pathogenesis of various lymphedema phenotypes has been unclear, but recent
reports indicate several chromosomal regions and genes which are involved in the
development of lymphedema. Congenital hereditary lymphedema (Milroy’s disease) was
linked to the VEGFR3 region on the distal chromosome 5q and missense mutations that
inactivate VEGFR-3 were found to be involved in the disease (Evans, 1999; Ferrell, 1998;
Irrthum, 2000; Karkkainen, 2000; Witte, 1998). While mutations which inhibit the biological
activity of VEGFR-3 are one cause of primary lymphedema, there are several families with
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Milroy’s disease and other lymphedema syndromes, which involve other genetic loci (Table
2). It is estimated that 5% of patients with primary lymphedema carry a mutation in the
VEGFR3 gene (D. Finegold, R. Ferrel, personal communication). For example, FOXC2 gene
mutations result in the rare hereditary lymphedema-distichiasis syndrome (Fang, 2000).
Characterization of other genes involved in the development of lymphedema syndromes will
give us more insight into the molecular mechanisms of lymphedema.
Table 2. Genetic alterations in lymphedema syndromes
Lymphedema
syndrome
Age at onset Gene loci Gene References
Milroy’s disease congenital 5q34-q35 VEGFR3 (Ferrell, 1998)
(Evans, 1999; Irrthum,
2000; Karkkainen, 2000;
Witte, 1998)
Lymphedema-
distichiasis
puberty 16q24.3 FOXC2 (Bell, 2001; Fang, 2000;
Finegold, 2001)
Cholestasis-
lymphedema
syndrome
puberty 15q Not known (Bull, 2000)
Turner syndrome congenital Xp11.2-
p22.1
Not known (Zinn, 1998)
Noonan syndrome congenital 12q24.1 PTPN11
(SHP-2)
(Tartaglia, 2001; White,
1984; Witt, 1987)
 (http://www3.ncbi.nlm.nih.gov/Omim/)
Lymphedema mouse models
Several experimental models of secondary lymphedema have been described including
lymphedema in the mouse tail (Swartz, 1996), rat hindlimb (Kriedman, 2002; Lee-Donaldson,
1999), or rabbit ear (Casley-Smith, 1977; Piller, 1978; S. Rockson, personal communication). In
addition, two existing mouse strains show phenotypes of primary lymphedema. In the Chy
mouse model, an inactivating VEGFR-3 mutation results in persistent hypoplasia of the
superficial lymphatic vessels. The subserosal lymphatic vessels are enlarged in these mice,
and this leads to formation of chylous ascites shortly after birth (Karkkainen, 2001). In another
mouse model, overexpression of the soluble extracellular domain of VEGFR-3 in mouse skin
competes for VEGF-C/VEGF-D binding with the endogenous receptor, leading to regression
of developing lymphatic vessels in several organs and resulting in lymphedema (Mäkinen,
2001a). However the lymphatic vessels regenerate during later postnatal development in most
organs, except in the skin. As in human lymphedema patients, both these mouse models show
swelling of the limbs due to hypoplastic/aplastic cutaneous lymphatic vessel network. Thus,
these  animal models provide us with tools to develop and test new therapies for lymphatic
dysfunction.
Prolymphangiogenic gene therapy
Development of strategies for local and controlled induction of lymphangiogenesis could
benefit the development of treatment for both primary and secondary lymphedema. The
discovery of specific genes and signalling cascades involved in regulation of lymphatic
vessel growth and in pathogenesis of lymphatic dysfunction have established a basis for the
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development of new targeted treatments
Previously, proangiogenic gene therapy in humans has shown promise in the treatment of
cardiovascular ischemic diseases (Blau and Banfi, 2001; Isner, 2002; Ylä-Herttuala, 2001).
Angiogenesis has been stimulated by overexpression of VEGF or various fibroblast growth
factors, using several different gene transfer vectors (Asahara et al., 1995; Ferrara and Alitalo,
1999). However, while VEGF is a potent inducer of angiogenesis, the vessels it helps to
create are immature, tortuous and leaky, often lacking perivascular support structures
(Carmeliet, 2000; Epstein, 2001). In addition, only a fraction of the blood vessels induced in
response to VEGF in the dermis and in subcutaneous fat tissue are stabilized and functional
in the skin (Pettersson, 2000; Sundberg, 2001b), and  intramuscular vessels develop into an
angioma-like proliferation or regress (Pettersson, 2000; Springer, 1998). Furthermore, edema
induced by VEGF overexpression complicates VEGF-mediated neovascularization, although
recent evidence suggests that it can be avoided by providing angiopoietin-1 for vessel
stabilization (Thurston, 2000; Thurston, 1999).
Vectors for gene therapy
When specific gene mutations of diseases are known, approaches to treat these diseases by
targeted gene therapy may be developed. Gene therapy is defined as the introduction of
genetic material into cells in order to achieve a therapeutic effect. Gene therapy can be used
in single gene disorders, such as cystic fibrosis, to replace the function of the mutated gene
(Flotte, 2001), or in cancer, to deliver a suicide gene to tumor cells (Alavi, 2001). There are
currently two types of vector systems used for gene therapy, viral and non-viral. In addition,
gene transfer can also be done ex vivo, by modifying cells from the patient in vitro and then
transplanting cells back to the target tissue.
Both viral and non-viral gene transfer vectors have been used in gene therapy trials in man.
For the most part, viral vectors are more effective than non-viral vectors for achieving high-
efficiency gene transfer. Non-viral vectors include liposome complexes and DNA conjugates.
These are both easy to produce, non-pathogenic and have been used in cardiovascular gene
therapy approaches because in this group of diseases the target tissue can be easily reached
through the vasculature (Isner, 2002; Ylä-Herttuala, 2001).
The most commonly used viral vectors include retroviruses, adenoviruses, adeno associated
viruses, lentiviruses and herpesviruses. Retroviruses can lead to stable integration of the
transfected gene into the host genome and produce long-lasting gene expression (Miller,
1988). However, retroviruses can deliver the transgene only to proliferating cells, which limits
their use (Miller, 1990). Currently retroviral vectors derived from the group of lentiviruses
(such as HIV-1) are being developed. The property of lentiviruses also facilitates retrovirally
mediated gene transfer to quiescent cells (Zufferey, 1997).
Recombinant adenoviruses are efficient and commonly used gene transfer vectors.
Adenoviruses can infect a wide variety of different cell types including both quiescent and
dividing cells (Berkner, 1988).  In the first generation of recombinant adenoviruses the viral
E1 gene region, that is crucial for the expression of other viral genes,  is deleted, which
makes virus replication deficient (Bett, 1993). Adenoviruses enter the cytoplasm by binding to
26
specific coxsackie/adenovirus receptors (CAR) and by secondary interaction with members
of the intergrin  family, which leads to the internalization of the virus (Roelvink, 1999; Stewart,
1997; Tomko, 1997; Wickham, 1993). Inside the cell, adenoviral proteins destroy the lysosome
and transgenes are transported to the nucleus. However, adenoviral transgenes remain
extrachromosomal in the cell and transgene expression is lost within a month, due to the
immune response directed towards the remaining viral proteins of the vector (Yang, 1996).
Current research with adenovirus vectors is focusing on strategies to circumvent the host
immune response to gain long term persistent transgene expression. Second generation
adenoviral vectors contain less viral genes and are therefore less immunogenic to the infected
host. Replication-competent adenoviruses are also being developed for gene therapy. For
example, the E1A gene can be inserted into a first generation recombinant adenovirus coding
a suicide gene under the regulation of a tumor-specific promoter (Miller, 1996). In theory,
when this kind of virus is inserted to tumor tissue, it could replicate specifically in tumor
cells and destroy the tumor (Miller, 1996).
Whereas the adenoviral gene transfer only provides short term expression, adeno associated
viruses (AAVs) provide transgene expression that may last for over a year (Daly, 2001).
AAVs are non-pathogenic human viruses, which do not elicit an inflammatory reaction or a
cytotoxic immune response, and they infect both dividing and non-dividing cells of several
organs (Reviewed in Monahan and Samulski, 2000). Viral entry to the cells is mediated by
several cell surface receptors, including heparan sulfates, αvβ5 integrins and FGFR-1(Qing,
1999; Summerford, 1999; Summerford and Samulski, 1998). AAVs are naturally replication
incompetent and they require additional genes from the helper viruses (adeno or herpes
viruses) for their replication (Monahan and Samulski, 2000). In addition, in the recombinant
AAVs viral rep and cap elements needed for virus production are deleted and therefore, in
order to replicate, recombinant AAV requires co-infection with both the helpervirus and the
wildtype AAV(Bordignon, 1995). One of the major limitations of AAV vectors is the limited
insert capacity of approximately 4.7 kb (Kremer, 1995). The wild type AAV integrates to host
chromosome 19. The integration of the recombinant AAVs is not known but there is possible
concern of insertional mutagenesis (Monahan and Samulski, 2000). Despite this, recombinant
AAV encoded Factor IX and CFTR (cystic fibrosis transmembrane regulator) gene transfers
have been successfully used to treat hemophilia B and cystic fibrosis, respectively (Kay, 2000;
Wagner, 1999). Studies have confirmed that AAV also gives long-term expression in man.
Tumorigenesis and metastasis
Tumorigenesis and tumor metastasis are multistep processes, and accumulation of several
genetic mutations are required for both processes. For a tumor cell to metastasize it must
pass through several barriers and finally survive and grow in the target tissue. First tumor
cells must enter the vasculature of the primary tumor. VEGF and bFGF, secreted by the
tumor cells, induce the expression of plasminogen activators and collagenases, contributing
to the degradation of basement membranes (Kalebic, 1983; Nagy, 1989). Because lymphatic
vessels start out as thin-walled, blind-ended sacs in extracellular tissue, in general, they can
be more easily penetrated by tumor cells than the blood vessels. However, tumor blood
vessels are abnormal, with fragmented and leaky basement membranes and according to
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some reports a considerable percentage of tumor blood flow is in direct contact with the
tumor cells (Hashizume, 2000). After overcoming the first vascular barrier the tumor cells
have to survive the blood or lymphatic vessel circulation and attach to the new target tissue
(lymph node or other target organ). Furthermore, in order to form a macrometastasis,
micrometastatic cells must also be able to induce angiogenesis in the target tissue. Therefore
many factors, such as proteolytic and migratory activity, the expression of adhesion
molecules and the deposition of the ECM surrounding the stromal and tumor cells contribute
to tumor growth and metastasis.
Most human tumors have their own characteristic way of metastasizing via lymphatic or
blood vessels to specific target tissues. The mechanisms determining these characteristics in
different tumor types remain poorly understood. In addition, certain tumor types rarely
metastasize. While angiogenesis is required for tumor growth (Folkman, 1971), it is not yet
clear to what extent active lymphangiogenesis occurs in human tumors. In tumors,
identification of lymphatic vessels is difficult. Of the known lymphatic specific markers, at
least VEGFR-3 and LYVE-1 have been shown to be expressed in some tumor blood vessels
(Niki, 2001; Partanen , 1999; Valtola, 1999, Padera, 2002). According to some analyses,
functional lymphatic vessels are absent from the interior of solid tumors, possibly due to
collapse of the vessels caused by the interstitial pressure induced by growing cancer cells
(Leu, 2000; Padera, 2002). Functional, enlarged lymphatics are, however, often detected in the
tumor periphery (Padera, 2002). In principle, tumor cells can either directly invade pre-
existing lymphatic vessels or new lymphatic vessels formed at the tumor periphery by tumor
induced lymphangiogenesis. As discussed in the previous chapter, tumor cells may use the
same trafficking pathways, chemokines and adhesion molecules as lymphocytes and antigen
presenting cells in order to gain access to the lymphatic vessels (Muller, 2001; Viley, 2001).
Role of VEGF-C and VEGF-D in tumors
Recent studies using experimental cancer metastasis models have characterized the possible
roles of VEGF-C and VEGF-D in tumor biology. To characterize the role of the VEGF-C in
tumor metastasis, mice overexpressing VEGF-C under the rat insulin promoter (Rip) were
generated.  These mice were then mated with mice that spontaneously develop pancreatic beta
cell tumors as a consequence of SV40 large T antigen oncogene expression driven by the
same Rip promoter (Mandriota, 2001). The tumors of Rip1Tag2 mice are capable of local
invasion, but do not induce lymphangiogenesis nor do they form metastases (Hanahan, 1985).
In the double transgenic model VEGF-C induced excessive lymphangiogenesis around the
pancreatic beta-cell tumors and this resulted in metastatic spread of tumor cells to pancreatic
and regional lymph nodes (Mandriota, 2001). These data suggest that the VEGF-C-induced
increase in peritumoral lymphatic vessels makes the lymphatics more accessible to the tumor
cells. Similarly, human breast cancer cells expressing ectopic VEGF-C were shown to induce
lymphangiogenesis in and around the implanted tumor cells resulting in enhanced tumor
metastasis to regional lymph nodes (Karpanen, 2001; Skobe, 2001a), and to the lung (Skobe,
2001a). Importantly, in the breast cancer model, VEGF-C-induced lymphangiogenesis and
intralymphatic tumor growth were inhibited by adenoviral expression of the soluble VEGFR-
3 protein (Karpanen, 2001). In the breast cancer models however VEGF-C did not have a
significant effect on tumor angiogenesis (Karpanen, 2001; Skobe, 2001a), whereas in a human
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malignant melanoma xenoplant model overexpression of VEGF-C resulted in both tumor
lymphangiogenesis and angiogenesis (Skobe, 2001b). VEGF-D has also been shown to
promote the metastatic spread of tumor cells via the lymphatic vessels (Stacker, 2001). In
addition, VEGF-D secreting tumors  had an increased growth rate and tumor angiogenesis.
The increased tumor angiogenesis, tumor growth and lymphatic metastasis were inhibited by
neutralizing antibodies against VEGF-D. The differences between tumor angiogenic
properties of VEGF-C and -D in different studies may be related to differences in proteolytic
processing of these growth factors in different tumor types.
More recent tumor animal models have shown that VEGF-C overexpressing tumors exhibit an
increase in lymphatic metastasis but no increase in the (hematogenous?) lung metastasis (He,
2002; Padera, 2002). Similarly, blocking of VEGFR-3 signalling by the soluble receptor body
suppressed tumor lymphangiogenesis and lymph node metastasis, but it did not have an effect
on lung metastasis ( He, 2002). Thus mechanisms of lymphatic and lung metastasis seem to
differ, at least in some tumor types. In addition, VEGF-C overexpression did not significantly
alter migration of the tumor cell lines in vitro, nor could it convert a low metastatic N15
human lung carcinoma cell line to an aggressive metastatic phenotype (Padera, 2002; He, 2002).
Tumor growth and metastasis are multistep processes and overexpression of VEGF-C seems
to be necessary but not sufficient for tumor metastasis.
Several recent reports have suggested a correlation between VEGF-C expression and
lymphatic metastasis in human tumors (Akagi, 2000; Bunone, 1999; Kitadai, 2001;
Kurebayashi, 1999; Niki, 2000; Ohta , 1999; Tsurusaki, 1999; Yonemura, 2001). Less is
known about the presense of VEGF-D in human tumors (Achen, 2001; Kurebayashi, 1999,
White, 2002). However, it is still unknown whether VEGF-C and VEGF-D expression can
promote lymphangiogenesis in human tumors and if this increase could then translate into a
higher rate of metastasis. Activation of the endothelium of lymphatic vessels in the tumor
periphery by growth factors or cytokines secreted by the tumor cells may also promote the
interaction of tumor cells with the lymphatic vessels and thus facilitate tumor metastasis.
Furthermore, both VEGF-C and VEGF-D increase vascular permeability and the resulting
increased interstitial pressure could facilitate tumor cell entry to both blood and lymphatic
vessels.  Although the preliminary results from animal models and patient studies have
suggested that VEGF-C and VEGF-D are involved in tumor metastasis, further studies are
required to evaluate the role of lymphatic endothelial growth factors in human tumors.
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AIMS OF THE STUDY
Previous studies have shown that VEGFR-3 is expressed specifically in lymphatic
endothelial cells and that its ligands VEGF-C and VEGF-D induce lymphangionesis in vivo
in transgenic mouse models. In human lymphedema patients, heterozygous inactivation of
VEGFR-3 has been shown to lead to primary lymphedema due to defective lymphatic
drainage in the limbs. The study presented here was carried out to characterize the expression
patterns of VEGF-C, VEGF-D and VEGFR-3 in human tissues and to analyse in vivo effects
of different VEGF-C forms in blood and lymphatic vessels when applied locally by viral
gene transfer.
The specic aims of the studies are listed here:
I Expression of VEGF-C and its receptor VEGFR-3 in the nasal respiratory mucosa
and in nasopharyngeal tumors
II  Expression patterns of VEGF-C, VEGF-D and VEGFR-3 in other human tissues
III In vivo effects of viral VEGF-C on blood and lymphatic vessels in the skin and
mucous membranes
IV Comparison of the effects of the native VEGF-C and the VEGFR-3 specific mutant
form of VEGF-C, VEGF-C156S
31
MATERIALS AND METHODS
I,II:  Analysis of VEGF-C, VEGF-D and VEGFR-3 expression in the
human tissues and human nasopharyngeal tumors
In order to characterize the expression patterns of VEGF-C, VEGF-D and VEGFR-3 in
human tissues and in nasopharyngeal tumors, fetal and adult patient samples were collected
and analysed by immunohistochemistry with different antibodies. Some of the results were
confirmed by comparative analysis of murine tissues.
Tissue samples
Fetal tissues were obtained from legal abortions of healthy women induced by prostaglandins
and the gestational age was estimated from the foot length (Munsick, 1984). Adult patient
samples were obtained from surgical specimens directly from the Department of Oto-rhino-
laryngology and from the Department of Pathology. All the studies were approved by the
Ethical Committee of the Helsinki University Central Hospital. The tissues were either fixed
in 4% paraformaldehyde or frozen in liquid nitrogen. The number of samples in each group
has been mentioned in publications I and II.
mRNA expression
Total RNA was isolated from frozen nasal and nasopharyngeal normal and tumor tissue
samples and Northern analysis was performed using probes for VEGF-C. Human endocrine
system Northern blot (Clontech) was used to compare VEGF-C and VEGF-D mRNA levels in
various endocrine organs.
Immunohistochemistry
Expression of VEGF-C, VEGF-D and VEGFR-3 was studied in the samples using
immunohistochemical analysis with several antibodies mentioned in publications I and II. Both
paraffin embedded and frozen sections were used. VEGF-C and VEGF-D antibodies were
validated by immunofluorescence staining of VEGF-C and VEGF-D transfected 293 EBNA
cells.
Confirming the VEGF-C and VEGFR-3 expression patterns in the nasal mucosa by In
Situ Hybridization and by β-Galactosidase staining of mouse embryos with the marker
gene.
In Situ Hybridisation of sections from E16.5 mouse embryos using probes for mouse VEGF-C
and VEGFR-3 was performed as described (Kaipainen, 1995). We also characterized the
expression pattern of VEGFR-3 in the nasal mucosa using mouse embryos in which one
VEGFR-3 allele is replaced by LacZ marker gene by knock-in strategy (Dumont, 1998).
Pregnant mice were sacrificed at E16.5 and the embryos were dissected and stained for β-
Galactosidase.
32
III, IV: In vivo effects of native VEGF-C and VEGFR-3 specific form of
VEGF-C.
After analysis of the expression patterns of VEGF-C and VEGFR-3 in human tissues, we
studied the in vivo effects of the full length VEGF-C on blood and lymphatic vessels in the skin
and respiratory tract. We compared the effects of adeno- and adeno associated virus (AAV)
mediated gene transfer of the full length VEGF-C, combination of VEGF-C and Ang-1 or a
control virus in the mouse (III). After this study we wanted to compare the effects of different
VEGF-C forms in viral and transgenic animal models (IV). We compared the effects of the
native full length VEGF-C and the VEGFR-3 specific mutant form of VEGF-C, called the
VEGF-C156S. In this mutant Cys156 of the native full length VEGF-C is replaced by Ser
residue by mutagenesis (Joukov, 1998). This single point mutation causes loss of VEGFR-2
binding making the VEGF-C156S a specific agonist for VEGFR-3.
Viral gene  transfer
For the adenovirus constructs, the full length human VEGF-C, VEGF-C156S and Ang1
cDNAs were cloned under the CMV-promoter. Replication-deficient E1-E3 deleted
adenoviruses were produced in 293 cells and concentrated by ultracentrifugation. As a
control virus we used adenovirus encoding nuclear targeted LacZ.  For the AAV construct,
the full length human VEGF-C and VEGF-C156S were cloned under the CMV-promoter and
the rAAVs (AAV serotype 2) were produced.  AAV encoding enhanced green fluorescent
protein (EGFP) was used as a control.
Animal models
Immunodeficient athymic nu/nu mice were used in order to study the in vivo effects of
different VEGF-C forms and the combination of VEGF-C and Ang1 in the skin and
respiratory mucosa. 1x108 – 9x108 pfus of adenoviruses or 5x109-1x1011 pfus of AAV were
injected either intradermally to the ear or to the nasal cavities (only adenoviruses) of the
mice. The analysis of the infected nu/nu mice was performed 2 days to 10 weeks after
infection. By using the Chy lymphedema mouse model our group had previously shown that
native VEGF-C gene transfer could be used as pro-lymphangiogenic gene therapy
(Karkkainen, 2001). In common with certain patients with Milroy’s disease, the Chy
lymphedema mice have a germline inactivating mutation of VEGFR-3 and they are lacking
the superficial lymphatic vessels of the skin (Karkkainen, 2001). The Chy mice do however
have one functional VEGFR-3 allele left, making VEGF-C gene therapy feasible (basic idea
of the VEGF-C gene therapy is explained in the Figure 6). In order to analyze the therapeutic
potential of the VEGFR-3 specific mutant form of VEGF-C (VEGF-C156S) we compared
the pro-lymphangiogenic effects of the native VEGF-C and VEGF-C156S in the Chy
lymphedema mice skin using AAV-vectors.
Analysis of the blood and lymphatic vessels
The blood vessels of the mouse skin and nasal cavity were visualized either by staining lectin
perfused ears or by whole mount immunohistochemistry using antibodies against PECAM-1.
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To visualize the lymphatic vessels we performed whole mount immunohistochemistry using
biotinylated polyclonal VEGFR-3 antibodies. The function of the lymphatic vessels in the skin
was analyzed by fluorescent microlymphangiography. We confirmed the results of the whole
mount analysis by staining the histological sections with antibodies against the mouse
podoplanin, LYVE-1, VEGFR-3 and PECAM-1, that can be used as lymphatic and blood
vessel markers.
The effects on permeability of VEGF-C and VEGF-C156S and the combination of VEGF-C
and Ang1 was studied by comparing the leakage of the Evans blue dye in ear skin when
injected in the tail vein of mice. Statistical analysis of the results of the permeability assay
was carried out by the Students t-test.
Transgenic approach
To confirm the result of the effects of the viral VEGF-C and VEGF-C156S we also compared
the effects of these factors using transgenic mouse models that overexpress VEGF-C and
VEGF-C156S under the K14-promoter in the skin keratinocytes (Jeltsch et al., 1997; Veikkola et
al., 2001). The lymphatic and blood vessels of these mice were analysed by mating them with
the heterozygous VEGFR-3/LacZ and VEGFR-2/LacZ mice in which one allele of the
VEGFR-3 or -2 gene is replaced by the LacZ marker gene. This allowed us to visualize the
VEGFR-3 and -2  positive vessels by β-galactosidase staining. The blood vessels of the adult
mice were visualized by lectin perfusion.
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RESULTS AND DISCUSSION
I Expression of VEGF-C and its receptor VEGFR-3 in nasal mucosa and
in nasopharyngeal tumors
Both blood and lymphatic vessels of the upper respiratory tract play important roles in
pathological conditions, such as infections and tumors. In the nasal mucosa unlike in other
parts of the respiratory tract, the permeability of the capillaries and small venules is very high
and their endothelium is typically fenestrated. The permeability of these vessels is further
regulated by controlling their thickness and amount of fenestrations. In the first study we
wanted to analyse the expression of VEGF-C and its receptor VEGFR-3 in the upper
respiratory tract. Previously, VEGFR-3 was reported to be a specific marker for the
lymphatic endothelium in adult tissues (Jussila, 1998; Kaipainen, 1995).
Our results demonstrate that unlike in most other adult tissues, in the nasal mucosa VEGFR-3
is expressed in some veins and capillaries. Expression of VEGF-C was detected in the
respiratory epithelial cells of the nasal mucosa. VEGF is more potent than histamine in
increasing capillary permeability and VEGF has previously been shown to induce
fenestrations in adrenal cortex capillary endothelial cells in culture (Esser, 1998; Roberts, 1997).
Inhibition of VEGF activity by specific monoclonal antibodies reduces vascular permeability
(Dvorak, 1995; Mesiano, 1998). VEGF mediates most of its blood vascular effects via VEGFR-
2. Thus, it is possible that VEGF-C, expressed by the nasal respiratory epithelial cells
regulates the permeablity and fenestration of the VEGFR-3 and VEGFR-2 positive blood
vessels in the respiratory mucosa. VEGF-C expression is upregulated by inflammatory
cytokines and recently expression of VEGF-C was reported to induce recruitment of
VEGFR-3 positive macrophages to the skin in an experimental melanoma model (Ristimaki,
1998; Skobe, 2001b). VEGF-C, expressed by the nasal respiratory epithelial cells, may
therefore contribute to the inflammary response of the mucous membrane by regulating the
permeability of the blood vessels and by inducing the recruitment of the inflammatory cells.
VEGF-C expression was also detected in nasal and nasopharyngeal tumors, which were
surrounded by VEGFR-3 positive angiogenic blood vessels. Several investigators have
reported VEGFR-3 expression in tumor blood vessels (Niki, 2001; Partanen, 1999; Valtola, 1999;
Beasley, 2002). Thus, VEGF-C may have a role as an adjunctive growth factor inducing tumor
angiogenesis. Recently, LYVE-1 was also reported to be expressed in some tumor blood
vessels in melanoma and fibrosarcoma models (Padera, 2002). Tumor blood vessels are
immature and consist of a heterogenous group of ECs (Ruoslahti and Rajotte, 2000).
Identification of tumor lymphatic and blood vessels is difficult and thus several vessel
specific markers should be used.
II  Expression of VEGF-C, VEGF-D and VEGFR-3 in normal human
tissues
In the second study we wanted to characterize in detail the expression pattern of VEGFR-3 in
different human tissues and to analyse which cell types express VEGF-C and VEGF-D. During
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murine embryogenesis, VEGFR-3 is initially expressed in angioblasts of head mesenchyme,
dorsal aorta, cardinal vein and allantois (Kaipainen, 1995; Dumont, 1998). At mouse embryonic
day 12.5 VEGFR-3 is expressed both in developing venous and presumptive lymphatic
endothelia, but later during development VEGFR-3 expression becomes largely restricted to
lymphatic endothelium (Kaipainen, 1995). VEGF-C mRNA is expressed in mesenchymal cells,
particularly in the regions where the lymphatic vessels undergo sprouting from the embryonic
veins (Kukk, 1996). High expression of VEGF-C is also detected in the murine mesenterium,
lung, hearth and kidney (Kukk, 1996).
Our results show that besides the lymphatic endothelium, VEGFR-3 was expressed in certain
fenestrated and discontinuous blood vessel endothelia. In most human tissues that have
continuous capillary endothelium, VEGFR-3 expression was restricted to the lymphatic
endothelia. Fenestrated capillary endothelia are found in the tissues where highly active
transport/exchange of molecules across the vessel wall is necessary. Such processes include
endocrine gland hormone secretion and the filtration of urine in the kidney glomeruli.
Discontinuous or sinusoidal capillary endothelia can be found in the liver, spleen and bone
marrow. All these tissues also participate in hematopoiesis and in blood cell trafficking.
VEGFR-3 may therefore play a role in regulating the translocation of the hematopoietic cells
across the endothelial wall. Interestingly, another lymphatic endothelial cell marker, LYVE-1
has also been reported to be expressed in the liver sinusoidal blood vascular endothelium
(Carreira, 2001). VEGFR-3 expression was also detected in the blood vascular channels of the
vertebral bodies. Non-endothelial expression of VEGFR-3 was detected in the notochordal
cells of 5 week old human embryos. This finding was consistent with previous findings in
avian embryos (Wilting, 1997). However, in avian embryos VEGFR-3 expression has also been
detected in the podocytes and in a subpopulation of bile duct epithelial cells (Wilting, 1997). The
role of VEGFR-3 in these cell types during embryonic development is not understood. As a
summary we can say that the expression pattern of VEGFR-3 differs depending on the tissue
and developmental stage, but in most adult human tissues VEGFR-3 expression is restricted to
LECs.
VEGF-C and VEGF-D, ligands of VEGFR-3, were found to be expressed in vascular smooth
muscle cells. In addition, intense cytoplasmic staining for VEGF-C was detected in
neuroendocrine cells, such as the α-cells of the islets of Langerhans, prolactin secreting cells in
the anterior pituitary, adrenal medullary cells and neuroendocrine cells of the gastrointestinal
tract. VEGF-D expression was detected in the innermost zone of the adrenal cortex and in
certain dispersed neuroendocrine cells. Like VEGF, both VEGF-C and VEGF-D are potent
vascular permeability factors and they may regulate the permeability and number of
fenestrations of the VEGFR-2 and/or VEGFR-3 positive the blood vessels in different organs.
Expression of VEGFR-3 in certain fenestrated and sinusoidal capillary endothelia may
potentiate the permeability regulation effects of VEGF-C and -D in some organs.
III In vivo effect of  VEGF-C on blood and lymphatic vessels
Following the results of the expression analysis we next characterized the in vivo effects of
VEGF-C in blood and lymphatic vessels. We overexpressed VEGF-C via adenovirus- and
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adeno associated virus -mediated transfection in the skin and in the respiratory tract of
athymic nude mice. In the previous studies, VEGF-C had been shown to induce hyperplasia
of cutaneous lymphatic vessels in both transgenic and adenoviral gene transduction models,
while causing very little or no angiogenesis (Enholm, 2001; Jeltsch, 1997; Veikkola, 2001).
However, our results showed that in addition to lymphangiogenesis viral VEGF-C also
induced enlargement, tortuosity and leakiness of veins and venules both in skin and in nasal
mucosa in a dose dependent manner. We also showed that in the skin VEGFR-2 was
expressed in the veins and in the collecting lymphatic vessels, whereas arteries were negative
for VEGFR-2. Smaller concentrations or longer periods (14-21 days) of adenoviral VEGF-C
expression resulted in a weaker blood vascular response while the lymphangiogenic response
was maintained. This is consistent with previous studies in which VEGF-C was reported to
be mainly lymphangiogenic in a transgenic mouse model and following adenoviral gene
transfer (Jeltsch, 1997; Enholm, 2001). The proteolytically processed 21kDa form of VEGF-C is
able to bind and activate VEGFR-2 (Joukov, 1997). However, the binding affinity of the 21
kDa form of VEGF-C to VEGFR-2 is 4-5 fold weaker than its affinity for VEGFR-3
(Mäkinen, 2001b). This may explain the strong dose-dependency of the blood vascular effects
of VEGF-C. Neutralizing VEGFR-2 antibodies have been shown to block the vascular
permeability effect of VEGF-C in tumor models, which further confirms that VEGF-C
induces vascular permeability via VEGFR-2 signalling (Kadambi, 2001). Our results also
demonstrated that VEGF-C is proteolytically processed in the skin. In the nasal mucosa the
blood vascular effect may also be mediated via VEGFR-3 which is expressed in the
fenestrated blood capillary endothelium.
Angiogenic sprouting of new blood vessels was not observed in response to AdVEGF-C or
AAV-VEGF-C. The enlargement of blood vessels in response to both AdVEGF-C and
AdVEGF in the skin may in part result from receptor-mediated vasodilation as the veins and
venules of the skin were shown to express VEGFR-2. VEGF-C has been shown to stimulate
release of endothelial nitric oxide, which is a potent mediator of vasodilation and which
could also contribute to enhanced vascular permeability (Witzenbichler, 1998). However, the
proliferation of the endothelial cells (intercalated or circumferential growth) could also
contribute significantly to the enlargement of the vessels. Consistent with this, some ECs of
the blood vessels were stained for the cell proliferation marker PCNA one week after
infection with the highest concentrations of AdVEGF-C. However, despite some proliferation
response in the ECs, new sprouting angiogenic blood vessels were not seen in AdVEGF-C
infected tissues unlike in the AdVEGF infected tissues. AdVEGF-mediated sprouting
angiogenesis has been reported to involve the detachment of VEGFR-1 expressing pericytes,
which are considered to stabilize blood vessels (Sundberg, 2001a). Failure of VEGF-C to
activate VEGFR-1 might thus contribute to the lack of sprouting angiogenesis in VEGF-C
overexpressing tissues, although enlargement of blood vessels can be induced by high
concentrations of VEGF-C.
VEGF-D is a close homologue of VEGF-C. The proteolytically processed short form of
human VEGF-D binds to and activates VEGFR-2 and VEGFR-3 (Achen, 1998). However,
unlike human VEGF-D, murine VEGF-D does not bind to mouse VEGFR-2, suggesting that
the biological functions of VEGF-D may differ in different species or that VEGF-D
signalling via VEGFR-2 is not significant for normal development and physiology (Baldwin,
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2001). Overexpression of the human VEGF-D in a mouse tumor xenocraft model did not
increase blood vessel permeability, even though it resulted in angiogenic and
lymphangiogenic responses (Stacker, 2001). In the the rat cremaster muscle, adenoviral
delivery of the short form of human VEGF-D induced predominantly angiogenic response
whereas it induced both lymphangiogenesis and angiogenesis in the rat skin (Byzova, 2002).
In the rabbit hindlimb ischemia model viral human VEGF-D was a very potent inducer of
blood vessel permeability and angiogenesis, whereas human VEGF-C had only marginal
effects on the blood vessels (J. Markkanen, T. Rissanen, S. Ylä-Herttuala, personal communication).
In an other study VEGF-C was reported to induce angiogenesis in the rabbit hindlimb
ischemia model (Witzenbichler, 1998). Thus, the in vivo effects of VEGF-C and VEGF-D seem
to differ in different animal models and tissues. Rabbit VEGF receptors have not been cloned
and we do not know to which rabbit receptor human VEGF-C and VEGF-D bind.
Differences in the proteolytic processing, availability of the receptors and vessel types may
modulate the biological effects of VEGF-C and VEGF-D. Furthermore, VEGF is know to be
upregulated normally during ischemia whereas VEGF-C is not (Plate, 1992; Shweiki, 1992;
Enholm, 1997). Therefore in the ischemic tissues VEGF-C may act as a adjunctive pro-
angiogenic growth factor by enhancing VEGF mediated angiogenesis.
Although VEGF was unable to induce the growth of new lymphatic vessels, it induced their
enlargement. This might be related to the VEGF-induced increased permeability and tissue
edema resulting in lymphatic vessel volume overload. However, VEGFR-2 was found to be
expressed in the deep collecting lymphatic vessels, and also weakly in the lymphatic
capillaries. Therefore VEGF induced enlargement of the lymphatic vessels might also be
related to intercalated growth of these vessels. Recent studies have suggested that adenoviral
VEGF can induce enlargement and proliferation of the lymphatic vessels (H.F. Dvorak,
personal communication). However, enhanced expression of VEGF by epidermal keratinocytes
in a transgenic mouse model did not cause changes in the skin lymphatic vasculature, despite
substantial edema (Detmar, 1998; Thurston, 1999).
Expression of angiopoietin-1 blocked the increased leakiness of blood vessels induced by
VEGF-C, while vessel enlargement and lymphangiogenesis were not affected. Previously
both transgenic and adenovirally administred Ang-1 have been reported to protect adult blood
vasculature against the plasma leakage induced by VEGF or inflammatory mediators
(Thurston, 2000; Thurston, 1999). In the transgenic model Ang-1 had effects on blood vessel
morphology, but  adenovirally mediated expression of Ang-1 did not change the morphology
of the blood vessels in the skin. The data from several mouse models suggests that Ang-1
signalling via Tie-2 is needed for the stabilization of the vessels and for the maintainance of
the interactions between the ECs and the surrounding ECM and mesenchyme (Sato, 1995;
Suri, 1997; Suri, 1998). Recent study of the Ang-2 null mouse has revealed that angiopoietins
are likely to play complex roles in the lymphatic system, which to date are poorly
understood. Mice lacking Ang-2 have lymphatic defects, but expression of Ang-1 in the Ang-
2 locus was sufficient to rescue the lymphatic phenotype (Gale, 2002). Tie-2 expression
pattern in the blood and lymphatic vessels is poorly characterized. As in angiogenesis,
angiopoietins may contribute to the remodelling and stabilization of the newly formed
lymphatic vessels. Further studies are needed to characterize the role of angiopoietins in
lymphatic vessel development.
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IV  Characterization of the VEGFR-3 specific mutant form of VEGF-C
(VEGF-C156S) as a lymphangiogenic factor
In the previous study (III) we had shown that high levels of native VEGF-C induce blood
vascular effects, including blood vessel enlargement and increased leakiness. In order to
develop a lymphatic specific gene therapy approach without the unwanted blood vascular
side effects, we studied the potential of a VEGFR-3 specific mutant form of VEGF-C
(VEGF-C156S) as a therapeutic agent in lymphedema. We compared the effects of native
VEGF-C and VEGF-C156S using transgenic mice that overexpress these growth factors
under the K14-promoter in the skin. In addition, we compared the effects of a virally
produced VEGF-C and VEGF-C156S in the skin. The results showed that overexpression of
VEGF-C156S potently induces lymphangiogenesis both during embryonic development and
in adult skin. Recombinant VEGF-C156S viruses were capable of inducing growth of
lymphatic vessels and the formation of new lymphatic sprouts, although this was less
pronounced than with native VEGF-C. In addition, we showed that VEGF-C156S had
minimal effects on blood vessels, in contrast to VEGF-C.
Previously VEGFR-3 signalling has been shown to be important for lymphatic endothelial
cell survival in vitro (Mäkinen, 2001a; Mäkinen, 2001b). Our results showed that a majority of
the lymphatic vessels formed in response to adenoviral VEGF-C expression regress when the
adenovirus was no longer active. In contrast, the AAV-mediated gene transfer resulted into
long-lasting transgene expression and therefore the VEGF-C induced lymphatic vessels were
sustained.
Whole mount images of ongoing embryonic and adult lymphangiogenesis suggested that the
mechanisms of lymphangiogenesis are very similar to those of angiogenesis (Risau, 1997) in
that lymphangiogenesis also appears to proceed via vessel enlargement, sprouting and
splitting (Figure 6). A previous study of the mechanisms of lymphangiogenesis in rat
jejunum also suggested that lymphangiogenesis occurs via sprouting and splitting (Shimoda,
2001). Although VEGF-C156S and VEGF-C both induced an increase in lymphatic
vascularity, their lymphangiogenic mechanisms seemed to differ. The difference between the
capacities of VEGF-C156S and VEGF-C to induce new lymphatic sprouts was most obvious
in the transgenic skin model. VEGF-C156S induced lymphatic vessel hyperplasia, whereas
VEGF-C induced a strong increase in the number of lymphatic vessels. This suggests that
activation of VEGFR-2 is required for the induction of lymphatic sprouting during embryonic
development. VEGFR-3 activation by VEGF-C156S seems sufficient for the induction of
lymphatic sprouting in adult tissues but a more robust growth signal may also require
VEGFR-2 signalling. Signalling via VEGFR-2 and VEGFR-3 receptor heterodimers may be
required for efficient formation of vessel sprouts. On the other hand, it is also possible that
VEGF-C is more effective in recruiting other effector cells and factors needed for
lymphangiogenic sprouting.
We also compared the effects of native VEGF-C and VEGF-C156S in Chy lymphedema
mice. Similar to certain patients with Milroy’s disease, the Chy lymphedema mice have a
germline inactivating mutation of VEGFR-3, which results in hypoplasia of cutaneous
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lymphatic vessels (Karkkainen, 2000; Karkkainen, 2001). Yet the mice have a normal deep
lymphatic network. We had previously analysed the effects of adenoviral and AAV-mediated
VEGF-C overexpression in Chy mice using microlymphangiography and
immunohistochemistry of the sections 2 weeks to 7 weeks after gene transfer (Karkkainen,
2001). The data showed that VEGF-C was sufficient for inducing growth of lymphatic vessels
in the Chy mouse model (Karkkainen, 2001). However, in the last study we wanted to compare
the effects of the different VEGF-C forms, to analyse the structure and morpholgy of the
vessel network in more detail and to characterize the longer follow-up effects of AAV-
mediated VEGF-C gene therapy.
Figure 6. VEGFR-3 whole mount staining of the lymphatic vessels in the skin. Ongoing
lymphangiogenesis in the AAV-VEGF-C infected skin. Enlargement of the lymphatic vessels,
sprouting (arrow) and splitting (arrowhead) of the vessels.
For the VEGF-C156S and VEGF-C gene transfer in the Chy mice we used AAV vectors that
result in long-lasting transgene expression (up to a year). Normally the Chy mice lack
functional superficial lymphatic vessels of the skin. However, fluorescent
microlymphangiography revealed that functional, normal-looking, but slightly dilated
lymphatic vessels had formed in the AAV-VEGF-C156S infected mice during the two-month
follow-up period and we also observed that in the AAV-VEGF-C infected Chy mice such
vessels persisted at least for 8 months. To characterize the morphology of the lymphatic
vessels in treated and untreated Chy mice, we visualized the lymphatic vessels of the skin by
VEGFR-3 whole-mount staining. In the AAV-EGFP treated or unreated Chy mice we could
detect only a few large sack-like vessel structures (Figure 7). AAV mediated gene expression
begins approximately 1 week after gene transfer. Three to five weeks after infection with
AAV-VEGF-C156S/VEGF-C we could detect sprouting of new VEGFR-3 posive vessels
from these lymphatic remnants. From 2 months after VEGF-C156S or VEGF-C gene transfer
branched lymphatic vessel network was detected in the skin (Figure 7). However, in most
cases the lymphatic vessels that formed in the skin of the Chy mice in response to the
lymphangiogenic gene therapy appeared slightly hyperplastic in comparison with those of
wild type mouse skin.
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Figure 7. Schematic illustration of the efficacy of VEGF-C gene therapy in primary lymphedema.
In the Chy lymphedema mice AAV mediated VEGF-C gene transfer is sufficient for inducing the
formation of a functional lymphatic vessel network in the skin. VEGFR-3 whole mount staining was
used to visualize the lymphatic vessels in treated and untreated Chy mice skin. The magnification is the
same in histological figures. Only few abnormal lymphatic remnant structures can be seen in the
untreated Chy mouse skin, whereas in the VEGF-C treated Chy mouse lymphatic vessels form a
hierarchic vessel network.
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The idea of VEGF-C gene therapy in primary lymphedema has been summarized in Figure 7.
VEGF-C therapy could probably also be used in the secondary lymphedema. In regional
lymphedema the treatment would be easier because local gene or protein transfer could be
used. Angiogenic gene therapy has raised concerns regarding the potential stimulation of
dormant tumor growth due to increased tumor angiogenesis in response to elevated systemic
VEGF levels. As tumor induced lymphangiogenesis has been associated with enhanced
metastasis to the lymph nodes (Mandriotta, 2001; Skobe, 2001; Stacker, 2001; Karpanen, 2001; He,
2002, Mattila, 2002), the risk of enhanced growth and spread of dormant metastases during
VEGF-C/D therapy needs to be carefully evaluated. Secondary lymphedema is common after
lymphadenectomy for the treatment of cancer. One possibility to improve the safety of the
VEGF-C/D therapy in these patients could be to combine the growth factor therapy with
microsurgical treatment. Surgeons have performed lymphatic-venous anastomoses in order to
reconstruct lymphatic drainage in patients with obstructive lymphedema (Campisi, 2002). By
combining this treatment with VEGF-C gene therapy one may reduce the extent of the
growth factor therapy and thus increase the safety of the treatment. The half-life of VEGF-C
in the blood circulation is short (Veikkola, 2001) and local VEGF-C therapy is thus likely to
function without systemic effects.
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CONCLUSIONS
Understanding the molecular mechanisms of different forms of lymphedemas and discovery
of lymphangiogenic growth factors and markers now allows us to develop targeted therapies
for disease involving lymphatic vessel dysfunction. The first lymphangiogenic growth
factors, VEGF-C and VEGF-D have been known for some years. Other molecules that have
been reported to be necessary for normal lymphatic development include the transcription
factor Prox-1, integrin α9  and Ang-2 (Huang, 2000; Wigle and Oliver, 1999; Gale, 2002). For
both pro- and anti-lymphangiogenic therapy approaches it is important to know the normal
physiological role of the growth factors that target the lymphatic vessels.
In the present study we have characterized expression patterns of VEGF-C and VEGF-D and
their receptors in normal human tissues. We have confirmed that VEGF-C/D receptor
VEGFR-3 is specific for lymphatic vessels in most human tissues, but it is also expressed in
some fenestrated capillary endothelia. VEGF-C was shown to be expressed by the
neuroendocrine cells and by the nasal respiratory epithelial cells and thus VEGF-C may
regulate the permeability of the nearby VEGFR-3 and VEGFR-2 positive fenestrated blood
vessels in these tissues. In addition we and others have shown that VEGFR-3 is upregulated
in some human tumor blood vessels and therefore VEGF-C may act as an adjunctive
angiogenic  factor in tumors. Using viral vectors in animal models we have described that in
addition to lymphangiogenesis native full length VEGF-C can induce enlargement and
leakiness of blood vessels via VEGFR-2. Importantly, Ang1 was shown to block the
permeability effect but not the lymphangiogenic effect of VEGF-C. Finally we have shown
that the VEGFR-3 specific mutant form of VEGF-C (VEGF-C156S) lacks the blood vascular
effects of  native VEGF-C. The new lymphatic vessels formed in response to AAV-mediated
VEGF-C gene transfer remained functional during the 8 month follow-up.
VEGF-C gene therapy may be a powerful tool in the treatment of various forms of human
lymphedema, once the problems with gene delivery can be solved. Patients with local
secondary lymphedema, without malignancies, would be the most suitable group for pro-
lymphangiogenic  therapy. Treatment of late stage lymphedema may be difficult because
long-term lymphedema results in accumulation of secondary changes in the tissues, such as
dermal fibrosis and fat deposition. However, advanced diagnostic methods, such as
lymphoscintigraphy, allow lymphedema diagnosis at an early stage. The treatment of
secondary lymphedema in patients with a history of a malignant disease may pose problems.
Whether VEGF-C or VEGF-D can enhance growth or lymphatic metastasis of dormant
tumors in these patients needs to be carefully considered. However, the half life of VEGF-C
in the systemic blood circulation is short and local VEGF-C gene therapy is not likely to
cause systemic effects (Veikkola, 2001).
Although the basic mechanisms of lymphangiogenic growth factors are now better known,
the molecular control of the formation of a patterned hierarchy of lymphatic vessels is still
unclear. Since both capillaries and collecting vessels are needed for lymphatic drainage, more
attention should be paid to the development of strategies to specifically target the different
types of lymphatic vessels. The blood vessels, formed in response to VEGF are immature,
tortuous and leaky and they often lack perivascular support structures (Carmeliet, 2000). This
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may also apply to the newly formed collecting lymphatic vessels. Characteristics and
function of the new lymphatic vessels formed in response to VEGF-C should be studied in
detail. Growth factor combinations could be utilized to create a better-functioning hierarchic
lymphatic network.  The identification of other growth factors involved in lymphatic vessel
formation and characterization of their specific roles in the process are needed. Cell-cell and
cell-matrix interactions possibly contribute to patterning and function of the lymphatic vessel
network, but the specific signalling cascades mediating these interactions are unknown.
Current data from our and other studies suggest that lymphangiogenesis in adults occurs by
outgrowth of new lymphatic vessels from the pre-existing vessels (Paavonen, 2000). However,
the potential role of lymphangioblasts in adult lymphagiogenesis requires further studies.
In the future, narrowing the target-cell range of the vector mediated gene expression would be
advantageous for all gene therapy approaches. Therapeutic applications may include targeting
of either gene expression or viral entry to the desired endothelial cells of the specific tissue
(Ruoslahti and Rajotte, 2000). Gene therapy vectors have been modified with homing peptides
or antibodies. Importantly, now that we have lymphatic and blood endothelial cell or pericyte
specific markers we could use these molecules for homing (Ruoslahti and Rajotte, 2000).
Alternatively, endothelial cell specific promoters could be used to achieve endothelial
expression of the therapeutic gene. The lymphatic endothelial cell specific promoters, such as
VEGFR-3 gene regulatory region could also be used to target the lymphatic endothelium (Iljin,
2001).  Combining growth factor or gene therapy with lymphatic microsurgery may also be
beneficial. Future studies will show the therapeutic potential and relevance of the pro-
lymphangiogenic and anti-lymphangiogenic therapies in human diseases.
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